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ABSTRACT
This retrospective study aimed to investigate the role that an RNA-binding 
protein, HuR, plays in the response of high-grade serous ovarian tumors to 
chemotherapeutics. We immunohistochemically stained sections of 31 surgically-
debulked chemo-naïve ovarian tumors for HuR and scored the degree of HuR 
cytoplasmic staining. We found no correlation between HuR intracellular localization 
in tumor sections and progression free survival (PFS) of these patients, 29 of whom 
underwent second-line gemcitabine/platin combination therapy for recurrent disease. 
Ribonucleoprotein immunoprecipitation (RNP-IP) analysis of ovarian cancer cells 
in culture showed that cytoplasmic HuR increases deoxycytidine kinase (dCK), a 
metabolic enzyme that activates gemcitabine. The effects of carboplatin treatment 
on HuR and WEE1 (a mitotic inhibitor) expression, and on cell cycle kinetics, were 
also examined. Treatment of ovarian cancer cells with carboplatin results in increased 
HuR cytoplasmic expression and elevated WEE1 expression, arresting cell cycle G2/M 
transition. This may explain why HuR cytoplasmic localization in chemo-naïve tumors 
is not predictive of therapeutic response and PFS following second-line gemcitabine/
platin combination therapy. These results suggest treatment of recurrent ovarian 
tumors with a combination of gemcitabine, carboplatin, and a WEE1 inhibitor may be 
potentially advantageous as compared to current clinical practices.
INTRODUCTION
Nearly 80% of ovarian cancer patients will have 
a favorable response to first-line therapy consisting 
of optimal surgical debulking followed by aggressive 
chemotherapy with paclitaxel and a platinum-based 
therapy [1]. Unfortunately, due to the development of 
chemoresistant disease, a majority of patients will develop 
recurrent tumors within 16-22 months. Gemcitabine in 
combination with carboplatin is commonly used as a 
second-line chemotherapy to treat recurrent disease. Some 
tumors respond better to a combination of gemcitabine and 
carboplatin than others, resulting in longer progression 
free survival (PFS). Unfortunately, the field does not have 
a reliable biomarker to determine which patients will 
respond well. Even when patients respond to the most 
aggressive therapy, almost all will eventually succumb to 
their disease.
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Gemcitabine acts as a prodrug that, when 
metabolized to gemcitabine di- and tri-phosphates, 
functions to inhibit DNA elongation, DNA repair enzymes, 
and RNA synthesis [2, 3]. Potential clinical relevance of an 
association between the amount of cytoplasmic localization 
of an RNA-binding protein, HuR, in tumor cells and the 
metabolic activation of gemcitabine has recently been 
identified [4, 5]. HuR functions in normal, healthy cells 
as a critical molecule involved in post-transcriptional 
gene regulation. When cells are stressed, e.g., by low 
oxygen levels, HuR potently influences translation of key 
survival and growth-related mRNAs in the cytoplasm by 
several mechanisms including active transport of mRNAs 
from the nucleus to the cytoplasm, mRNA stabilization, 
and direct facilitation of translation. In line with these 
functions, HuR has been identified as a marker for poor 
prognosis in many cancers, including ovarian cancer 
[6–8]. In two small cohorts of pancreatic cancer patients 
treated with gemcitabine following surgery, a significant 
association between increased overall survival and high 
HuR expression in the cytoplasm has been identified, 
suggesting that HuR subcellular localization might serve 
as a predictive marker for gemcitabine response [4, 5]. 
Enhanced gemcitabine functionality in tumors is likely the 
consequence of increased production of the key nucleoside 
analog metabolizing enzyme, deoxycytidine kinase (dCK) 
resulting from post-transcriptional regulation of dCK 
mRNA by HuR [4, 5, 9, 10]. In this study, we sought, 
but found no evidence, that HuR cellular localization 
might serve as a predictive marker for clinical outcome 
following gemcitabine treatment of recurrent ovarian 
tumors. We explored potential reasons why this might be 
the case. The results of our findings suggest that improved 
clinical outcomes for ovarian cancer patients might be 
better achieved using gemcitabine in combination with 
carboplatin and a WEE1 inhibitor as a second-line therapy.
RESULTS AND DISCUSSION
Is HuR cellular localization in ovarian tumors 
predictive of favorable tumor response to 
gemcitabine?
We investigated whether there is a correlation 
between subcellular localization of HuR in tumor cells 
and PFS of ovarian cancer patients receiving gemcitabine 
as a second-line therapy for recurrent tumors. Sections of 
thirty-one ovarian tumor specimens from patients treated 
with gemcitabine were immunostained for HuR. Twenty-
nine of the specimens were from chemo-naive tumors (i.e., 
surgically-debulked tumors prior to any chemotherapy), 
while two were from secondary surgically-debulked 
tumors following first-line chemotherapy with carboplatin 
and paclitaxel (Figure 1A). Twenty-nine of the 31 tumor 
specimens were from patients receiving second-line 
therapy with gemcitabine in combination with one or 
more chemotherapeutics – 26 with carboplatin, 1 with 
carboplatin and avastin, and 2 with cisplatin (Table 1). 
Two of the 31 tumors had HuR expression in only a few 
nuclei and no cytoplasmic HuR, 1/30 had only nuclear 
staining, while HuR was present in at least 50% of nuclei 
and in the cytoplasm of 28/30 tumors. The amount of 
cytoplasmic HuR in these 28 tumors varied: 7 were 
scored +/-, 9 were +, 6 were ++, and 6 were +++ (Figure 
1B). To assess whether the amount of cytoplasmic HuR 
expression in tumors was predictive of PFS following 
gemcitabine/carboplatin, we compared PFS of patients 
whose tumors had low cytoplasmic HuR expression (-, 
+/-, +; n=19; median = 8 mo) with that of patients whose 
tumors had high cytoplasmic HuR expression (++ and 
+++; n=12; median = 8 mo) (Figure 1C). There was no 
significant difference in PFS (p=0.58). Even when tumors 
that were scored as + were grouped with ++ and +++ 
tumors, there was no significant difference in PFS (- and 
+/-; n=9; median = 8 mo) and (+, ++, +++; n=22; median 
= 8 mo) (p=0.62). The two tumor specimens that were 
collected after first-line therapy had cytoplasmic HuR 
scores of + and +++, and had PFS values of 3 mo and 4 
mo, respectively. The PFS of the 3 patients whose tumors 
had no detectable HuR in the cytoplasm was near or 
above the median value (8 mo, 8 mo, 12 mo). These data 
provide no evidence to support the use of HuR subcellular 
localization as a predictive marker for ovarian tumor 
sensitivity to second line treatment with gemcitabine. We 
note, however, a correlation of lower tumor grades (Grades 
I and II) with low cytoplasmic HuR, and Grade III tumors 
with high cytoplasmic HuR approached significance 
(p=0.066) (Figure S1).
Patients in this study were treated with different 
numbers of cycles of carboplatin/paclitaxel (1X, n=18; 2X, 
n=7; 3X, n=2; 4X, n=3; 5X, n=5), thereby contributing 
variability to the duration of first-line carboplatin/
paclitaxel therapy and the time between assessment of 
HuR localization status in surgically-debulked tumors 
and the initiation of gemcitabine treatment. In addition, 
patients were treated with different numbers of cycles 
of gemcitabine as second-line therapy (range 2-11), 
with most patients treated 5 (n=8) or 6 (n=11) times, 
and with gemcitabine in combination with different 
chemotherapeutic drugs. These variables may contribute to 
our failure to identify a correlation between HuR cellular 
localization in ovarian tumors and PFS as was observed 
in pancreatic adenocarcinoma where gemcitabine is 
administered to patients as a first-line therapy. We 
investigated possible molecular mechanisms that might 
be operative in the context of these variables.
dCK activates gemcitabine in ovarian cancer 
cells
Deoxycytidine kinase (dCK) is the rate 
limiting metablic enzyme that phosphorylates 
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deoxyribonucleosides as well as their nucleoside 
analogs (e.g., gemcitabine) [11]. To confirm that dCK 
activates gemcitabine in ovarian cancer cells, as has been 
demonstrated in pancreatic cancer cells [4], we transiently 
transfected A2780 cells with siRNA against dCK 
(siDCK) or siControl (siCtrl) for 24 h, then treated cells 
with various concentrations of gemcitabine for 48 h and 
measured viable cells. In parallel cultures, we confirmed 
dCK suppression in siDCK-transfected cells by western 
blot analysis (Figure S2). dCK inhibition resulted in ~80% 
increase in cell number when cells were treated with 0.005 
and 0.01 μM gemcitabine as compared to gemcitabine-
treated siCtrl-transfected and untransfected cells (p<0.005) 
(Figure S2). These results support gemcitabine activation 
by dCK in ovarian cancer cells.
HuR binds to dCK mRNA in ovarian cancer cells
HuR protein binds to specific mRNA transcripts 
in a highly regulated process subject to modifications of 
HuR protein itself (e.g., phosphorylation and methylation) 
and to competition with miRNAs for binding sites [12–
16]. We have shown that, upon gemcitabine treatment, 
HuRbinds to dCK mRNA in pancreatic tumor cells, 
resulting in increased dCK protein and activity [4]. In 
addition, we have shown a strong correlation between 
dCK and HuR cytoplasmic expression in pancreatic 
ductal adenocarcinomas [9]. Our recent studies identified 
specific mRNAs bound to HuR in ovarian and pancreatic 
cancer cells that are unique to these two cancer types [17, 
18]. It is therefore possible that HuR may not directly 
associate with dCK mRNA in ovarian cancer cells as it 
does in pancreatic cancer cells, thereby offering a possible 
explanation why HuR cytoplasmic localization failed to 
serve as an informative marker for gemcitabine sensitivity. 
To test whether HuR translocation from the nucleus to the 
cytoplasm in response to gemcitabine correlates with an 
increase in dCK expression in ovarian cancer cells, we 
treated OVCAR5 cells with 0.02 μM gemcitabine (IC
50
), 
prepared cytoplasmic and nuclear protein fractions at 
various time points, and analyzed the amount of HuR 
and dCK proteins in these two cellular compartments on 
Figure 1: Analysis of HuR subcellular localization in ovarian tumor specimens and corresponding progression free 
survival of patients. A. Treatment protocol for ovarian cancer patients with recurrent tumors. B. Ovarian tumor sections immunostained for 
HuR and representative of how staining intensity was scored. C. Kaplan-Meier plot of progression free survival (PFS) of patients with tumors 
having relatively low HuR cytoplasmic staining (scored -, +/-, or +) and tumors having high cytoplasmic HuR staining (scored ++ or +++).
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western blots. Cytoplasmic HuR and dCK levels peaked 
between 16 h and 48 h after gemcitabine treatment (~1.5-
fold higher than level at 0 h) (Figure 2A). An increase in 
dCK mRNA was also observed by qRT-PCR during this 
timeframe (Figure 2B). Increased cytoplasmic HuR at 
48 h after gemcitabine treatment was also observed by 
immunofluorescent staining (Figure 2C). The amount 
of nuclear HuR, however, appeared unchanged upon 
gemcitabine treatment (Figure 2A), most likely due to 
masking of subtle changes in its abundance that are not 
detected on western blots. The same analysis of another 
ovarian cancer cell line, A2780, confirmed the association 
of gemcitabine-induced elevation of cytoplasmic HuR 
and dCK mRNA/protein (Figure S3). Sections of human 
ovarian tumors immunostained for HuR and dCK revealed 
a positive correlation (p=0.008) between cytoplasmic 
HuR expression and dCK expression (Figure 2D). These 
results show that gemcitabine treatment induces HuR 
translocation to the cytoplasm and that this translocation 
is associated with increased dCK expression in ovarian 
cancer cells.
The dCK 3’UTR region contains 8 putative HuR 
recognition motifs [19]. To determine whether HuR 
binds directly to dCK mRNA in ovarian cancer cells, we 
performed RNP-IP assays on lysates prepared from A2780 
cells grown in the presence or absence of gemcitabine for 
12 hours. An RNP-IP with a HuR-specific antibody was 
performed to isolate total mRNA transcripts associated 
with HuR, followed by qRT-PCR to determine the amount 
of dCK mRNA associated with HuR protein. IgG RNP-IP 
was performed as a negative control (Figure 3). The dCK 
mRNA level was increased 4-fold in gemcitabine-treated 
cells compared to untreated cells. SUMO-1 mRNA, a 
HuR target (unpublished, Brody Lab), served as a positive 
Table 1: Profile of patients in this study
Age (yrs) 61.8 +/- 9.3*
Race
Caucasian (29)
African American (2)
Stage
Ib (1)
Ic (1)
II (1)
IIb (1)
IIc (1)
IIIb (1)
IIIc (24)
unstaged (1)
Grade
g2 (4)
g2-3 (3)
g3 (24)
Histology
serous (27)
serous/endometrioid (1)
serous w/mucinous features (1)
carcinosarcoma + serous (1)
serous w/clear cell features (1)
Optimal debulking
20 optimal
11 sub-optimal
# first-line therapy carboplatin + paclitaxel cycles 1.8 +/- 1.1* (range: 1-5)
# second-line gemcitabine cycles
(i.e., treatment of recurrent tumors)
5.1 +/- 1.9* (range: 3-11)
Second-line gemcitabine therapy
combined with other chemo?
Carboplatin (26)
Carboplatin + avastin (1)
Cisplatin (2)
None (2)
Progression Free Survival (mo) 8.5 +/- 4.8* (range: 3-26)
*Mean +/- S.D.
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Figure 2: HuR nuclear to cytoplasmic translocation following treatment of OVCAR5 cells with gemcitabine (GEM) 
associated with an increase in cytoplasmic dCK mRNA and protein. A. Western blot analysis for HuR and dCK in cytoplasmic 
and nuclear protein lysates. GAPDH provided loading control and allowed for quantitative comparison of HuR and dCK at different time 
points (values indicated beneath HuR and dCK panels). Lamin A/C provides marker for cytoplasmic extract purity. B. qRT-PCR analysis 
of cytoplasmic dCK mRNA isolated from OVCAR5 cells treated with GEM for different times (mean +/- SD). C. OVCAR5 cells grown 
in medium +/- GEM and immunostained for HuR. White arrows point to cytoplasmic HuR. D. Sections of human ovarian tumor, collected 
prior to drug treatment, were immunostained for HuR and dCK. Boxed area is enlarged in lower left corner of each panel in top row.
Figure 3: RNP-IP assays showing increased binding of dCK mRNA to HuR in response to gemcitabine. A. HuR protein-
bound dCK (left) and SUMO-1 (right) mRNA amounts in A2780 cells grown in the presence or absence of 1μM GEM for 12 h as measured 
by qPCR (mean +/- SD). B. Left: Western blots of protein lysates prepared from A2780 cells grown in the presence or absence of 1 μM 
GEM, before immunoprecipitation, and immunoprecipitates prepared with anti-HuR. Three separate IPs were assayed. Right: Western blots 
of protein lysates before immunoprecipitation, and immunoprecipitates prepared with IgG.
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control and was enriched ~2 fold upon gemcitabine stress 
(Figure 3). The same study performed in OVCAR3 cells 
confirmed the observation that dCK mRNA isolated from 
HuR RNP-IP samples were significantly enriched (Figure 
S4). These results indicate that HuR binds directly to dCK 
mRNA in ovarian cancer cells, just as it does in pancreatic 
cancer cells.
HuR suppression reduces dCK expression and 
gemcitabine efficacy
To study HuR regulation of dCK further, we 
examined the effect of HuR silencing on dCK expression. 
We generated an ovarian cancer cell line, OVCAR5-
shHuRc257 that stably expresses short hairpin RNA 
(shHuR) [17]. We stressed OVCAR5, OVCAR5-shCtrl, 
and OVCAR5-shHuRc257 cells with 0.02 μM gemcitabine 
for 0, 6, 12, 24, 48, and 72 h, then prepared whole cell 
lysates to measure dCK expression on western blots 
(Figure 4). dCK protein expression in gemcitabine-treated 
OVCAR5 and OVCAR5-shCtrl cells increased (35-84%) 
in a time dependent manner (Figure 4). In contrast, dCK 
expression in gemcitabine-treated OVCAR5-shHuRc257 
cells remained unchanged at all time points except 72 
h when a minor increase was observed (Figure 4). A 
small increase in total HuR expression was observed in 
gemcitabine-treated OVCAR5-shHuRc257 cells. This 
observation likely reflects previous reports of HuR self-
regulation [20–22].
Figure 4: HuR suppression inhibits increase in dCK expression in response to GEM. Western blot analysis of HuR and dCK 
protein expression in OVCAR5, OVCAR5-shCtrl, and OVCAR5-shHuR cells treated with or without 0.02 μM gemcitabine (GEM) for 
indicated times.
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Next, we determined the impact of HuR inhibition 
on ovarian cancer cell sensitivity to gemcitabine. 
We treated two cell lines, OVCAR5-shHuRc257 
and OVCAR3-shHuRi699, a doxycycline (DOX)-
inducible HuR-targeted shRNA ovarian cancer cell 
line, with various gemcitabine concentrations for 72 
h, and then assessed cell viability. HuR suppression in 
OVCAR5-shHuRc257 and DOX-induced OVCAR3-
shHuRi699 cells compared to control cells resulted in 
reduced sensitivity to gemcitabine (Figure 5). In sum, 
these experiments show that HuR translocation to the 
cytoplasm in response to gemcitabine exposure results 
in increased dCK expression. This, in turn, results in 
enhanced gemcitabine therapeutic efficacy in ovarian 
cancer cells. It is clear that there must be another 
confounding factor or factors that compromise the value 
of HuR cellular localization as a predictive marker of 
second-line gemcitabine efficacy.
Combination chemotherapy abrogates HuR’s 
ability to act as a predictive marker for 
gemcitabine efficacy
Nearly all of the tumor samples examined in 
our patient study (29/31) were obtained from surgical 
debulking procedures performed prior to first-line 
carboplatin/paclitaxel treatment. Given our previous 
study in which we showed HuR translocation from the 
nucleus to the cytoplasm in pancreatic cancer cells upon 
stress with DNA-damaging anticancer agents including 
carboplatin and paclitaxel [23], it is reasonable to expect 
an increase in cytoplasmic HuR in response to exposure 
to first-line treatment, far in advance of gemcitabine/
carboplatin second-line therapy. The fact that 12/29 
of the tumors had significant cytoplasmic HuR prior to 
first-line therapy, and the PFS of these patients was not 
significantly different from that of patients with low 
cytoplasmic HuR, is further evidence that the complexity 
Figure 5: HuR suppression reduces gemcitabine chemotherapeutic efficacy. A. Number of OVCAR5-shCtrl or OVCAR5-
shHuR cells at 72 h following treatment with different concentrations of GEM. Western blot analysis of HuR of whole cell lysates in 
OVCAR5-shCtrl or OVCAR5-shHuR cells (mean +/- SD). B. Numbers of OVCAR3-shHuRi699 cells treated with +/- 0.1μg/ml DOX and 
with different GEM concentrations. Western blot analysis of HuR in OVCAR3-shHuRi699 cultured in GEM-containing medium with or 
without DOX (mean +/- SD). shHuRi = inducible shHuR; shHuRc = constitutively expressed shHuR. *indicates p<0.05
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of HuR biology abrogates its use as a predictive marker 
for efficacy of gemcitabine second-line therapy. Ideally, it 
would be preferable to determine HuR status just prior to 
gemcitabine therapy, but surgical debulking of recurrent 
tumors is rarely performed, limiting the clinical feasibility 
of attaining tumor specimens.
Another complication is that gemcitabine is 
nearly always administered to ovarian cancer patients in 
combination with one or more chemotherapeutics, usually 
carboplatin. A recent study showed that DNA-damaging 
radiation therapy, given in combination with gemcitabine, 
may disrupt HuR’s ability to act as an informative 
biomarker (9). Expression of WEE1, a mitotic inhibitor 
kinase that regulates the DNA damage repair pathway, is 
present in ovarian cancer ascites following chemotherapy 
[24]. We have shown that an increase in HuR in response 
to DNA-damaging chemotherapeutics (e.g., carboplatin) 
results in elevated WEE1 in pancreatic cancer cells [23]. 
Elevated Wee1, in turn, promotes cell-cycle arrest at the 
G2/M transition and ensuing resistance to DNA-damaging 
agents. To explore whether HuR regulation of WEE1 
provides a mechanism underlying the lack of improved 
PFS associated with cytoplasmic HuR in ovarian tumors 
of patients treated with a combination of gemcitabine 
and carboplatin, we first assayed HuR expression in 
OVCAR5 cells treated with 7.5 µM carboplatin (IC
50
) for 
various times. Cytoplasmic HuR began to increase after 
24 h treatment with carboplatin and reached a maximum 
increase of 1.6-fold higher than in non-treated cells at 48 
h (Figure 6A). The amount of nuclear HuR remained high 
in treated cells at all time points. WEE1 expression also 
increased in carboplatin-treated OVCAR5 cells, reaching 
a peak expression at 48 h, similar to HuR, whereas no 
increase in WEE1 was observed in carboplatin-treated 
OVCAR5-shHuR cells in which HuR expression was 
significantly inhibited (Figures 6A-6D). WEE1 protein 
increased 1.3-fold in HuR-expressing OVCAR5-shCtrl 
cells upon carboplatin treatment (Figure 6B & 6C).
We also determined the effect of HuR-regulated 
WEE1 expression on cell-cycle kinetics in the context of 
carboplatin treatment (Figures S5A & B). We observed 
that a higher percentage of cells accumulated in the G2/M 
phase in OVCAR5-shCtrl cells (29.5%) as compared to 
OVCAR5-shHuR (22.3%) 48 h after 7.5 µM carboplatin 
treatment (Figure S5B). Under normal culture conditions, 
the percentage of OVCAR5-shCtrl and OVCAR5-shHuR 
Figure 6: Cytoplasmic HuR increase in response to carboplatin increases WEE1 expression. A. Western blot analysis of 
HuR and WEE1 proteins in OVCAR5 cells treated with 7.5 μM carboplatin for various times (0-72 h). Cytoplasmic and nuclear extracts 
were analyzed separately for HuR expression. GAPDH (a cytoplasmic marker) and Lamin A/C (a nuclear marker) analysis was also done 
to evaluate purity of cytoplasmic and nuclear extract preparations. B. WEE1 expression in OVCAR5 cells stably transfected with shHuR or 
with shCtrl (whole cell extracts). C. Cytoplasmic HuR and WEE1 expression in OVCAR5 cells treated with carboplatin for various times. 
Numbers in panels A and B indicate expression levels of HuR and WEE1 normalized to GAPDH. D. Sections of human ovarian tumor, with 
high (left) and low (right) HuR and WEE1 expression collected prior to drug treatment, immunostained for HuR and WEE1.
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cells in the G2/M phase is similar (Figure S5B). In 
agreement with these in vitro observations, human ovarian 
tumor sections immunostained for HuR and WEE1 
revealed a positive correlation between cytoplasmic HuR 
expression and WEE1 expression (p=0.048) (Figure 
6D). These results offer a mechanism to explain why 
cytoplasmic localization of HuR is not predictive of a 
favorable outcome to gemcitabine treatment in our study 
when given as a combination therapy with carboplatin.
Since arrest of DNA replication by insertion of 
the gemcitabine analogue metabolite, triphosphate 
cytosine, is dependent on cell division, its effectiveness 
is likely to be compromised to some degree in cell cycle-
arrested carboplatin-treated cells even though dCK 
metabolizes gemcitabine as a consequence of elevated 
HuR cytoplasmic expression. Clinical experience clearly 
shows, however, that in ovarian cancer patients with 
platinum-sensitive relapse, progression-free survival is 
prolonged when gemcitabine is given in combination with 
carboplatin as compared to carboplatin monotherapy [25]. 
Evidence suggests that this synergy may result from the 
inhibition of repair of platinum-induced DNA cross-links 
by gemcitabine [26, 27]. Our results suggest that patients 
with recurrent tumors be treated first with gemcitabine 
followed by treatment with carboplatin. To test directly the 
effect of WEE1-mediated cell cycle arrest on gemcitabine 
efficacy, we measured survival of OVCAR5 cells grown in 
medium containing various concentrations of gemcitabine 
in the presence or absence of siWEE1. WEE1 inhibition 
increased the sensitivity of cells to gemcitabine 2-4 fold 
over the range of tested gemcitabine concentrations, and 
decreased the IC
50
 from 0.02 to 0.004 μM (Figure 7). This 
result suggests that it may also be advantageous to combine 
inhibition of WEE1 with gemcitabine andcarboplatin as 
a combination second-line therapy, thereby overcoming 
cell-cycle arrest and enhancing the therapeutic response 
to gemcitabine in patients with platinum-sensitive relapse. 
A small molecule WEE1 inhibitor, MK-1775, has been 
shown to enhance antitumor efficacy of p53-deficient 
tumor cells to DNA-damaging agents including cisplatin, 
carboplatin, gemcitabine and 5-fluorouracil [28–30], and 
a Phase II clinical trial (NCT02101775) testing MK-1775 
in combination with gemcitabine to treat recurrent ovarian 
cancer is currently recruiting. Given our understanding of 
how gemcitabine affects tumor cell survival, addition of 
gemcitabine to this therapeutic strategy may have added 
benefit to all patients independent of p53 status.
Figure 7: WEE1 inhibition sensitizes OVCAR5 cells to gemcitabine. A. OVCAR5 cells were transfected with siWEE1 or siCtrl 
for 6 h. Following addition of gemcitabine at various concentrations to the culture medium, cell viability was assayed after 72 h. B. Western 
blot of WEE1 in gemcitabine-treated OVCAR5 cells treated with siHuR or siCtrl. α-tubulin serves as a gel loading control. *indicates 
p<0.0001
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One limitation of our study is that HuR localization 
was analyzed in only one ovarian cancer subtype, serous 
ovarian tumors, a large majority of which were high-grade 
tumors. While this subtype accounts for ~70% of ovarian 
tumors, these tumors differ from other tumor subtypes 
(endometrial, clear cell, mucinous) not only in morphology 
but also in gene expression profile, molecular genetic 
features, genetic and epidemiologic risk factors, precursor 
lesions, pattern of spread, and of particular relevance to 
this study, response to platinum-taxane based treatment 
[31, 32]. Indeed, expression of hENT1, dCK, 5’NT, and 
RRM1 was found to be higher in undifferentiated and 
clear cell carcinoma as compared to serous ovarian tumors 
[33]. Given these substantial differences, the possibility 
that HuR localization might be an informative marker for 
gemcitabine response in other ovarian tumor subtypes 
warrants further study.
MATERIALS AND METHODS
Patient population
Medical records from our gynecologic oncology 
practice (CJD) at the Lankenau Medical Center, 
Wynnewood, PA, were reviewed to identify ovarian 
cancer patients who had undergone surgical debulking and 
first-line treatment with carboplatin and paclitaxel, who 
subsequently developed recurrent tumors and underwent 
further therapy with gemcitabine in combination with 
carboplatin (26/31) or other chemotherapeutic (3/31). 
Using patients’ medical record numbers to assure sample 
de-identification, archival paraffin blocks of tumor 
tissue from 31 patients were retrieved and sections were 
prepared. This protocol was approved by the Lankenau 
Medical Center Institutional Review Board. The patient 
profile is summarized in Table 1 . Progression free survival 
time was determined by CA125 Resist based on serial 
CA125 measurements, as well as on CT scans.
Generation of HuR knock-down cell lines
HuR stable knock-down cell lines were generated 
in our lab as previously described [17]. Briefly, to 
generate OVCAR5 cells stably-expressing shHuRc257 
(“c” for constitutive) or shCtrl, cells were infected with 
shHuRc257- or shCtrl-expressing lentivirus. Twenty-
four hours after viral infection, shHuRc257- or shCtrl-
expressing cells were selected in medium containing 
hygromycin B (Gemini #400-123). To generate OVCAR3 
Dox-inducible shHuRi699 cells (“i” for inducible), cells 
were infected with shHuRi699-expressing lentivirus. 
Forty-eight hours post-viral infection, shHuR- or shCtrl-
expressing cells were selected in medium containing 
puromycin dihydrochloride (Gemini # 400-128P).
Cell Culture, transfection, chemo-treatment, and 
viability assay
OVCAR5 cells (A. Klein-Szanto, Fox Chase 
Cancer Center) and A2780 cells (T. Hamilton, Fox Chase 
Cancer Center) were maintained in RPMI-1640 medium 
(Cellgro) supplemented with 10% FBS (Gemini) at 
37°C in 5% CO
2
. OVCAR3 cells were purchased from 
American Type Culture Collection (ATCC) and grown 
in media as recommended by ATCC. All cells tested 
negative for mycoplasma using a PCR kit (Sigma 
#MP0035-1KT). For in vitro transfection, cells were 
transiently transfected with siDCK (Ambion #4390824), 
siWEE1 (Thomas Scientific Dharma #GLEKC-000008), 
or siControl (Ambion #AM4611) using Lipofectamine 
2000 (Invitrogen) according to the manufacturer’s 
directions. To determine effects of gemcitabine on HuR 
and dCK expression, or carboplatin on HuR and WEE1 
expression, cells were incubated in IC
50
 concentrations 
of gemcitabine (0.02 μM) or in carboplatin (7.5 μM) 
for various times, then harvested for Western blot 
analysis. To determine effects of gemcitabine on HuR 
knockdown cell proliferation, OVCAR5-shHuRc257 
cells were incubated with various concentrations of 
gemcitabine for 72 hours and OVCAR3-shHuRi699 cells 
were incubated with 1µg/ml doxycycline and various 
concentrations of gemcitabine for 72 hours, after which 
viable cell number was determined using EZ Count Kit 
(Rockland #KLD-001). All cell viability assays were 
done in triplicate.
Immunoblot analysis
To prepare whole cell extracts, cells were 
homogenized in RIPA buffer containing proteinase 
inhibitors and centrifuged at 12,000 rpm for 15 min at 
4°C. Cytoplasmic and nuclear cell extracts were prepared 
[Nuclear and Cytoplasmic Extraction kit (Pierce #78833)] 
and protein concentration of extracts was determined 
[BCA Protein Assay Kit (Pierce #23225)]. Soluble 
proteins were separated on 10% SDS-PAGE gels and 
analyzed by Western blotting using antibodies toHuR 
(1:1000) (clone 3A2; Santa Cruz Biotechnology), dCK 
(1:500) (clone 2243C2; Santa Cruz), WEE1 (1:1000) 
(clone B11; Santa Cruz), lamin A/C (1:1000) (clone 636; 
Santa Cruz Biotechnology), or GAPDH (1:8000) (clone 
5C6; Ambion). Blots were washed several times with 
PBST (phosphate buffered saline, 0.1% Tween), then 
incubated with horseradish peroxidase-labeled goat anti-
mouse (1:8000) (Thermo Scientific) secondary antibody. 
Proteins were visualized with ECL (Pierce #32106). 
Densitometry quantification of proteins was done using 
Image J software.
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Immunostaining
Antigen retrieval was performed on deparaffinized 
tumor sections by steam heating for 30 min in citrate 
buffer followed by endogenous peroxidase quenching 
with 3% H
2
O
2
/methanol for 20 min. Cells were grown in 
chamber slides, then fixed in cold acetone at -20°C for 
10 minutes. Tumor sections or cells were incubated with 
primary antibody and biotinylated secondary antibody. 
Signals were amplified and visualized either using the 
TSA-Plus Fluorescence System (Perkin Elmer) according 
to manufacturer’s instructions, or using avidin/biotin 
complex system (VECTASTAIN Elite ABC kit from 
VECTOR Laboratories) followed by DAB visualization 
and hematoxylin counterstaining. Slides were imaged 
with a Zeiss Axiovert 200M microscope or Zeiss Axioplan 
microscope. Human ovarian tumor HuR cytoplasmic 
staining was scored as -, +/-, ++, or +++. Stained sections 
were viewed and scored twice by two different pairs of 
investigators (JAS and WP; JAS and GSD) who were 
blind to PFS of each patient. Anti-HuR monoclonal 
antibody 19F12 (1:5000) was from Clonegene. Anti-dCK 
(Abcam #ab151966) was from Abcam. Anti-WEE1 (clone 
B-11) was from Santa Cruz.
Ribonucleoprotein-immunoprecipitation  
(RNP-IP)
RNP-IPs were performed as described [34]. 
Briefly, A2780 or OVCAR3 cells were treated with 1µg/
ml gemcitabine for 12 hours, then cytoplasmic lysates 
were obtained using CelLytic NuCLEAR Extraction Kit 
(Sigma-Aldrich, #NXTRACT) according to manufacturer’s 
instructions, with the modification of supplementing with 
100 U/ml RNase inhibitor (Life Technologies, # N8080119) 
to preserve RNA integrity. HuR protein and its bound 
mRNA cargo were immunoprecipitated by incubating the 
cytoplasmic lysates with mRNP-IP-grade HuR antibody 
(MBL International Corp. #RN004P) or isotype control IgG 
(Santa Cruz #sc-2027) pre-coated to Protein A-Sepharose 
beads (Sigma-Aldrich #P9424). HuR was digested with 
proteinase K (Life Technologies, cat. #AM2546). After IP, 
the RNA was isolated and cDNA synthesized (A&B applied 
biosystems #4368814). GAPDH and dCK transcripts 
were quantified by real-time PCR analysis (#4352024) 
using specific probes, dCK (#Hs01040726_m), 18S 
(#Hs99999901_s1), and SUMO-1(#Hs02339312_g1) (A&B 
Applied Biosystems).The relative levels of dCK product 
were first normalized to 18S product in all IP samples, then 
fold changes in HuR-IP were compared with IgG-IP.
Statistical analysis
The distribution of PFS was estimated using 
the Kaplan-Meier method and association of HuR 
expression with PFS was assessed using the log-rank test. 
Correlations of tumor grade with HuR expression, HuR 
and dCK expression, and HuR and WEE1 expression were 
evaluated using Fisher’s exact test.
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